Delay in Receipt of Proceeds from Self-Held Convertible Bond Sale by 2 Months... Increased Liquidity Pressure
GeneOne Life Science filed a correction report delaying the receipt date of proceeds from the sale of its 6th series self-held convertible bonds (face value 1.5B KRW) from May 29, 2026 to July 29, 2026, a 2-month postponement.
The buyer is Seonkwang System Co., Ltd., an unrelated party, selected for operational fund raising. The purpose of the sale is to secure working capital.
These bonds were originally issued on Nov 4, 2025 at 5B KRW face value, of which 3B was repurchased early. The current sale involves 1.5B of those repurchased bonds. The conversion price is 2,192 KRW per share (86% premium to current price of 1,180), making conversion economically unattractive at current levels.
The delay in proceeds receipt may disrupt short-term liquidity planning, potentially negatively impacting operations and investment activities.
Although this transaction does not directly dilute equity, the existence of convertible bonds represents a potential dilution risk if the stock price rises above the conversion price.
[AI Comprehensive Analysis]The delay in receiving proceeds from the self-held convertible bond sale indicates a setback in the company's funding schedule. Despite the high conversion price relative to the current stock price, the issuance of convertible bonds itself can be a financial burden. Short-term liquidity risk may increase, warranting investor caution.
KOSPI Filing Information
Filing: [Correction of Description] Report on Major Matters (Decision on Sale of Self-Convertible Bonds)